Myeloproliferative neoplasms:ten years after the discovery of JAK2 V617F gene mutation

Abstract

This article focuses on the rapidly evolving understanding of the molecular pathogenetic mechanisms of the bcr-abl-negative myeloproliferative neoplasms (MPN) [myeloproliferative disorders (MPD)], such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). The amplify therapies were reviewed and IFN-α is an effective agent for these MPN (MPD). Also, the article emphasize once again avoidance MPN and select MPD for such chinese patients. Key words: Myeloproliferative neoplasms, MPN; Myeloproliferative disorders, MPD; JAK2 V617F gene mutation; Interferon-alpha